eprintid: 27252
rev_number: 20
eprint_status: archive
userid: 1249
dir: disk0/00/02/72/52
datestamp: 2019-10-10 11:33:07
lastmod: 2020-02-19 07:58:07
status_changed: 2019-10-10 11:33:07
type: article
metadata_visibility: show
creators_name: Téoule, Patrick
creators_name: Trojan, Jörg
creators_name: Bechstein, Wolf
creators_name: Woeste, Guido
title: Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer
subjects: 610
divisions: 61200
keywords: Gastric cancer , Neoadjuvant chemotherapy , Postoperative morbidity
note: Dieser Beitrag ist aufgrund einer (DFG-geförderten) Allianz bzw. Nationallizenz frei zugänglich.

This publication is freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.
abstract: Background/Aims: Patients with locally advanced gastric cancer benefit from neoadjuvant chemotherapy. Potential disadvantages of neoadjuvant chemotherapy include increased surgical complications, leading to increased postoperative morbidity. 

Methods: We retrospectively studied medical records of 135 patients with resectable cancer of the stomach who underwent gastrectomy between 2002 and 2009. The impact of neoadjuvant chemotherapy on postoperative morbidity was investigated. We compared demographic, clinical and operative data, morbidity and mortality from 105 patients who received surgical treatment immediately after diagnosis (SURG group), versus 30 patients who first received neoadjuvant chemotherapy (CHEMO group). 

Results: Demographic, clinical and surgical procedure parameters did not differ significantly between both groups. Postoperative morbidity was 46.7% in CHEMO- and 41.9% in SURG-patients (p = 0.680). There were eight cases of death, 2/30 (6.7%) in CHEMO and 6/105 (5.7%) in the SURG group (p = 1). The overall complications according to Clavien- classification did not differ significantly (p = 0.455). The wound infection rate (23.3 vs. 3.8%; p = 0.002) and  insufficiency of the duodenal stump (13.3 vs. 1.9%; p = 0.022) were significantly higher in the CHEMO group. 

Conclusion: This study showed no significant impact of neoadjuvant chemotherapy on postoperative morbidity after gastrectomy using the Clavien-classification. Only an increase in wound infections in CHEMO compared with the SURG group were noted. Therefore, neoadjuvant chemotherapy can be considered safe and feasible.
date: 2015
publisher: Karger
id_scheme: DOI
id_number: 10.11588/heidok.00027252
official_url: https://doi.org/10.1159/000381884
ppn_swb: 1678729116
own_urn: urn:nbn:de:bsz:16-heidok-272529
language: eng
bibsort: TEOULEPATRIMPACTOFNE2015
full_text_status: public
publication: Digestive Surgery
volume: 32
number: 4
place_of_pub: Basel
pagerange: 229-237
issn: 0253-4886 (Druck-Ausg.), 1421-9883 (Online-Ausg.)
citation:   Téoule, Patrick ; Trojan, Jörg ; Bechstein, Wolf ; Woeste, Guido  (2015) Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer.  Digestive Surgery, 32 (4).  pp. 229-237.  ISSN 0253-4886 (Druck-Ausg.), 1421-9883 (Online-Ausg.)     
document_url: https://archiv.ub.uni-heidelberg.de/volltextserver/27252/1/381884.pdf